Simulations Plus, Inc. (SLP)
| Market Cap | 367.74M -32.8% |
| Revenue (ttm) | 80.54M +2.5% |
| Net Income | -62.79M |
| EPS | -3.12 |
| Shares Out | 20.21M |
| PE Ratio | n/a |
| Forward PE | 45.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,162,288 |
| Open | 18.17 |
| Previous Close | 18.14 |
| Day's Range | 18.15 - 18.21 |
| 52-Week Range | 11.09 - 21.01 |
| Beta | 1.32 |
| Analysts | Hold |
| Price Target | 17.25 (-5.22%) |
| Earnings Date | Jul 9, 2026 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SLP stock is "Hold." The 12-month stock price target is $17.25, which is a decrease of -5.22% from the latest price.
News
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation...
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether...
Simulations Plus advances agentic drug development with NVIDIA BioNeMet Agent
Simulations Plus (SLP) announced it is building the agentic layer of Composer using the NVIDIA (NVDA) BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, ...
Simulations Plus Transcript: Status update
OBESITYsym, a mechanistic QSP model, predicts weight loss and nausea for various obesity treatments, validated across drugs and dosing regimens. It supports translational predictions, adapts to new mechanisms, is being enhanced with AI, models distinct populations like type 2 diabetes, and is validated against recent clinical trial outcomes.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that he...
Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP
LOS ANGELES--(BUSINESS WIRE)---- $SLP--Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP.
Simulations Plus downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Simulations Plus (SLP) to Hold from Buy with an $18.50 price target after the company entered into an agreement to be acquired by affiliates of Altaris for $18.50…
Simulations Plus downgraded to Market Perform from Outperform at William Blair
William Blair analyst Max Smock downgraded Simulations Plus (SLP) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by affiliates…
Leerink says Certara peer acquisition supports higher multiple
Leerink sees Certara’s (CERT) valuation as overly depressed given what remains a highly profitable entity with multiple long-term growth drivers. This morning’s acquisition of peer Simulations Plus (S...
Simulations Plus trading resumes
09:55 EDT Simulations Plus (SLP) trading resumes
Simulations Plus to be acquired by Altaris for $18.50 per share in cash
09:02 EDT Simulations Plus (SLP) to be acquired by Altaris for $18.50 per share in cash
Simulations Plus to be acquired by Altaris for $18.50 per share in cash
Simulations Plus (SLP) entered into a definitive agreement to be acquired by affiliates of Altaris in an all-cash transaction. At or about the closing of the transaction, Altaris anticipates the…
Simulations Plus to Be Acquired by Altaris For Approximately $375 Million
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus trading halted, news pending
08:55 EDT Simulations Plus (SLP) trading halted, news pending
Securities Investigation Into Simulations Plus, Inc. (SLP) Continues — Investors Who Lost Money Encouraged to Contact Johnson Fistel
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation...
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The i...
Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and dire...
Johnson Fistel Investigates Simulations Plus, Inc. (SLP) After Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws.
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
Simulations Plus, Inc. (SLP) Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
San Diego, California--(Newsfile Corp. - June 3, 2026) - Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securi...
Simulations Plus, Inc. (SLP) Securities Fraud Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Outlook Revision, Impairment Charge, and Auditor Dispute
SAN DIEGO--(BUSINESS WIRE)---- $SLP #AuditorDispute--Johnson Fistel, PLLP is investigating potential claims on behalf of Simulations Plus, Inc. (NASDAQ: SLP) investors concerning whether the Company o...
Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $SLP #Inc--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directo...
Simulations Plus, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws. T...
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus, Nvidia collaborate to scale AI-assisted modeling workflows
Simulations Plus (SLP) announced the launch of a technical collaboration with NVIDIA (NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive model...